About this trial
The aim is to determine whether whether Tph could support non-infectious complications through providing help to pathological B-cells.
Eligibility criteria
Qualifiers
Male or female;
Age ≥ 18 years;
Standard criteria will be applied to diagnose CVID, specifically requiring: 1) low serum IgG level <5 g/L, combined with low IgM- and/or IgA-isotype concentrations <0.4 g/L or <0.7 g/L, respectively; 2) poor antibody responses to immunization or infection; and 3) exclusion of other defined forms of secondary hypogammaglobulinemias. Patients meeting the definitional criteria for CVID will be included, regardless of the duration of the disease or the treatment received (gammaglobulins substitution or not);
Being affiliated to health insurance;
Disqualifiers
Patients on corticosteroids and/or immunosuppressants;
Patients with a primary immunodeficiency genetically characterized, such as Bruton disease our HyperIgM syndrome;
Patients with an active chronic infection;
Pregnant or breastfeeding women;
Trial design
Treatments tested in this trial
- blood sample